白细胞介素6作为抑郁症治疗靶点:一项概念验证随机临床试验
这项4周双盲安慰剂对照概念验证试验纳入30例难治性抑郁症伴低度炎症患者,单次静脉输注托珠单抗或生理盐水。主要终点第14天抑郁躯体症状未达统计学显著,但第28天缓解率和应答率数值上优于安慰剂,且耐受良好。
要点
- 托珠单抗组第28天缓解率53.9% vs 安慰剂31.3%,应答率46.2% vs 18.8%,但未达统计学显著。
- 基线hs-CRP水平而非IL-6水平与抑郁改善相关,提示hs-CRP或可预测免疫治疗反应。
- 托珠单抗耐受良好,无严重不良事件或退出,支持开展大规模疗效试验。
核心结论
- 在难治性抑郁症伴低度炎症患者中,单次托珠单抗输注未在第14天显著改善抑郁躯体症状,但第28天缓解率和应答率数值上优于安慰剂,需大规模试验验证。
研究设计与样本
- 4周概念验证、双盲、平行组、安慰剂对照随机临床试验,2018至2022年从初级和二级医疗及自我转诊招募30例成人难治性抑郁症伴低度炎症患者。
主要发现
- 第14天抑郁躯体症状调整均数差为-0.12(95%CI -2.51至2.28),未达统计学显著。
- 第28天托珠单抗组缓解7例(53.9%)vs 安慰剂5例(31.3%),NNT=5;应答6例(46.2%)vs 3例(18.8%),NNT=4。
- 托珠单抗在躯体症状、抑郁严重度、疲劳、心理症状、状态焦虑和生活质量上呈逐步改善趋势,第28天效应最大。
- 基线hs-CRP水平而非IL-6水平与抑郁改善相关。
- 托珠单抗耐受良好,无严重不良事件或退出。
关键数值与推荐
- 纳入标准:ICD-10中重度抑郁、抗抑郁药反应差、hs-CRP≥0.3 mg/dL(两次检测)、Beck抑郁量表II躯体症状评分≥7。
- 干预:单次静脉输注托珠单抗8 mg/kg(最大800 mg/患者)或生理盐水。
- 主要终点:输注后14天抑郁躯体症状;次要终点:抑郁总严重度。
临床怎么用
- 对于难治性抑郁症伴低度炎症(hs-CRP≥0.3 mg/dL)且躯体症状明显的患者,抗IL-6治疗可能是有前景的研究性选项。
- 基线hs-CRP或可作为预测免疫治疗反应的生物标志物,而非IL-6水平。
- 当前证据仅为概念验证,尚不能常规临床使用托珠单抗治疗抑郁症。
局限性
- 样本量小(30例),研究为概念验证性质,未达统计学显著。
- 随访仅4周,长期疗效和安全性未知。
- 单次输注设计,未评估重复给药效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Interleukin 6 (IL-6), a keystone inflammatory cytokine, is a credible mechanistic candidate for causing depression. However, randomized clinical trials testing its treatment potential remain scarce. OBJECTIVE: To identify likely treatment-sensitive outcomes and effect size for systemic IL-6 inhibition in patients with difficult-to-treat depression. DESIGN, SETTING, AND PARTICIPANTS: This 4-week, proof-of-concept, double-blind, parallel-arm, placebo-controlled randomized clinical trial recruited adults with moderate-to-severe International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) depression, poor antidepressant response, low-grade systemic inflammation (high-sensitivity C-reactive protein [hs-CRP] level ≥0.3 mg/dL on 2 tests), and depression somatic symptoms (Beck Depression Inventory II somatic symptoms score ≥7) from primary and secondary care and self-referral from 2018 to 2022. Participants were randomized into minimization balanced groups on depression severity and sex. Assessments were conducted at baseline and 7, 14, and 28 days after infusion. Data were analyzed from 2023 to 2025. INTERVENTION: Single intravenous infusion of IL-6R antagonist tocilizumab (8 mg/kg, maximum 800 mg/patient) or normal saline. MAIN OUTCOMES AND MEASURES: The primary outcome was depression somatic symptoms at 14 days after infusion. The secondary outcome was total depression severity. Exploratory outcomes included fatigue, anxiety, anhedonia, quality of life, and cognition. Outcomes were assessed using validated scales and interpreted against clinically meaningful thresholds. RESULTS: A total of 30 participants (mean [SD] age, 41.1 [12.3] years; 24 [80.0%] female) were randomized, including 14 in the tocilizumab group and 16 in the placebo group. Of these, 29 participants received the assigned infusion and completed follow-up. As expected for a small proof-of-concept study, no results reached statistical significance, including little improvement in depression somatic symptoms at day 14 (adjusted mean difference: -0.12; 95% CI, -2.51 to 2.28). However, a pattern of greater stepwise improvement over time was observed with tocilizumab in somatic symptoms, depression severity, fatigue, psychological symptoms, state anxiety, and quality of life, with the largest effects observed at the final follow-up (day 28). Tocilizumab may also improve more individual depressive symptoms. Treatment effects were within ranges considered clinically meaningful for depression severity, fatigue, anxiety, and quality of life. At the final follow-up, remission (7 participants [53.9%] vs 5 participants [31.3%]; number needed to treat [NNT] = 5) and response (6 participants [46.2%] vs 3 participants [18.8%]; NNT = 4) rates favored tocilizumab compared with placebo. Baseline hs-CRP level, but not IL-6 level, tracked depression improvement, suggesting hs-CRP may better predict immunotherapy response in depression than drug-specific biomarkers. Tocilizumab was well tolerated, with no serious adverse events or withdrawals. CONCLUSIONS AND RELEVANCE: These findings highlight treatment-sensitive outcomes, effect sizes, and patient selection methods for testing systemic IL-6 inhibition in patients with difficult-to-treat depression, and call for a large-scale efficacy trial of anti-IL-6 treatment in depression. TRIAL REGISTRATION: isrctn.org Identifier: ISRCTN16942542.
引用
- Foley ÉM, Turner N, Margelyte R, et al. Interleukin 6 as a Treatment Target for Depression: A Proof-of-Concept Randomized Clinical Trial. JAMA Psychiatry. 2026. PMID: 42160062. doi:10.1001/jamapsychiatry.2026.1053
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。